Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Down 30.2% in October

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a large drop in short interest in October. As of October 15th, there was short interest totaling 276,200 shares, a drop of 30.2% from the September 30th total of 395,900 shares. Based on an average daily volume of 1,300,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 5.0% of the shares of the stock are sold short. Approximately 5.0% of the shares of the stock are sold short. Based on an average daily volume of 1,300,000 shares, the days-to-cover ratio is currently 0.2 days.

Liminatus Pharma Stock Down 3.8%

Shares of LIMN traded down $0.05 on Tuesday, hitting $1.27. 120,528 shares of the stock traded hands, compared to its average volume of 941,008. The stock has a market cap of $34.38 million and a price-to-earnings ratio of -25.40. The firm has a 50 day moving average price of $1.78. Liminatus Pharma has a 1 year low of $1.11 and a 1 year high of $33.66.

Liminatus Pharma (NASDAQ:LIMN) last announced its quarterly earnings data on Friday, October 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter.

Analysts Set New Price Targets

LIMN has been the topic of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Liminatus Pharma in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Liminatus Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, August 30th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.